Former CereDx rebranding as Valtari Bio. Discusses clinical trial progress.

Morgantown, WV and San Diego, CA – January 11th, 2017 – The stroke-diagnostic firm, CereDx, announced today that it is rebranding as Valtari Bio. Valerie Gionis, COO stated, “The biotech marketplace is full of firms with quasi-descriptive names. The challenge with that approach is that many industry professionals and partners are confused by the similarity of the actual firm names. So, we decided to take an innovative approach and invent our own word. Our science is clearly unique from everything else we’ve seen in stroke diagnostics. We decided to take a similar tactic with our new name.”

The name change comes at a particularly exciting time for the firm. Richard Giersch, CEO, reported that Valtari Bio’s first clinical trial (VALISS), being conducted at the University of Cincinnati, is running smoothly.  “We knew going into the trial that the accuracy of our proprietary biomarkers was exceptional. We had clinical trial data on over 500 patients confirming that; this trial is enabling us to further optimized our biomarker profile.” Once combined with an enabling technology at the point of care, Valtari Bio will change the landscape of stroke diagnosis. This technology will save brain function, and lives.” Giersch did not reveal specific trial details. “It’s too soon for that, before the start of the VALISS clinical trial we knew that our profile was performing much better than the current standard of care, further optimizing it for high clinical confidence is key to adoption and utilization and the focus of our efforts.”

About Valtari Bio

Valtari Bio™ is developing a blood test to aid in the rapid and unbiased diagnosis of suspected stroke patients. Our ReST™ (Rapid evaluation Stroke Triage) test will help doctors and nurses, with or without stroke expertise, make a confident initial stroke versus stroke mimic diagnosis in ten minutes or less. Currently, initial diagnosis happens within minutes of the patient’s arrival for treatment and is based solely on a clinician’s assessment of symptoms and rudimentary stroke scale checklists. The lack of unbiased tools for triaging suspected stroke patients results in misdiagnosis rates as high as 30% in urban areas and 60% in rural areas. Physicians need a rapid and confident method for making an initial unbiased diagnosis of stroke versus no stroke.

Media & Investor Contact
Valerie M. Gionis, COO
Valtari Bio Inc.
media@valtaribio.com
+1 304-825-3131

Valtari_Bio_logo_horizontal